LEAP2 deletion in mice enhances ghrelin's actions as an orexigen and growth hormone secretagogue
Objective: The hormone liver-expressed antimicrobial peptide-2 (LEAP2) is a recently identified antagonist and an inverse agonist of the growth hormone secretagogue receptor (GHSR). GHSR's other well-known endogenous ligand, acyl-ghrelin, increases food intake, body weight, and GH secretion and...
Saved in:
Main Authors: | Kripa Shankar (Author), Nathan P. Metzger (Author), Omprakash Singh (Author), Bharath K. Mani (Author), Sherri Osborne-Lawrence (Author), Salil Varshney (Author), Deepali Gupta (Author), Sean B. Ogden (Author), Shota Takemi (Author), Corine P. Richard (Author), Karabi Nandy (Author), Chen Liu (Author), Jeffrey M. Zigman (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disrupting the ghrelin-growth hormone axis limits ghrelin's orexigenic but not glucoregulatory actions
by: Deepali Gupta, et al.
Published: (2021) -
"A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes"
by: Deepali Gupta, et al.
Published: (2021) -
A long-acting LEAP2 analog reduces hepatic steatosis and inflammation and causes marked weight loss in mice
by: Kripa Shankar, et al.
Published: (2024) -
Ghrelin mediates exercise endurance and the feeding response post-exercise
by: Bharath K. Mani, et al.
Published: (2018) -
Fasting induces remodeling of the orexigenic projections from the arcuate nucleus to the hypothalamic paraventricular nucleus, in a growth hormone secretagogue receptor-dependent manner
by: Agustina Cabral, et al.
Published: (2020)